In another single prospective trial, 118 patients with BRAF-mutated NSCLC, of which 17 BRAF non-V600E (4 G466, 4 G469, 1 G596, 5 K601, and 3 N581), were treated with vemurafenib. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.